A citation-based method for searching scientific literature

Diana Cristina Henao-Carrillo, Oscar M Muñoz, Ana M Gómez, Martín Rondón, Christian Colón, L Chica, Claudia Rubio, Fabián León-Vargas, Maria Alejandra Calvachi, Ana María Perea. J Clin Transl Endocrinol 2018
Times Cited: 7







List of co-cited articles
37 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections.
Richard M Bergenstal, Timothy S Bailey, David Rodbard, Monika Ziemen, Hailing Guo, Isabel Muehlen-Bartmer, Andrew J Ahmann. Diabetes Care 2017
70
57

International Consensus on Use of Continuous Glucose Monitoring.
Thomas Danne, Revital Nimri, Tadej Battelino, Richard M Bergenstal, Kelly L Close, J Hans DeVries, Satish Garg, Lutz Heinemann, Irl Hirsch, Stephanie A Amiel,[...]. Diabetes Care 2017
668
57

Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.
T Heise, L Nosek, S G Bøttcher, H Hastrup, H Haahr. Diabetes Obes Metab 2012
225
42

More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial.
Julio Rosenstock, Alice Cheng, Robert Ritzel, Zsolt Bosnyak, Christine Devisme, Anna M G Cali, Jochen Sieber, Peter Stella, Xiangling Wang, Juan P Frías,[...]. Diabetes Care 2018
101
42


Glycemic Variability in Type 1 Diabetes Compared with Degludec and Glargine on the Morning Injection: An Open-label Randomized Controlled Trial.
Ryo Iga, Hiroshi Uchino, Ken Kanazawa, Shuki Usui, Masahiko Miyagi, Naoki Kumashiro, Hiroshi Yoshino, Yasuyo Ando, Takahisa Hirose. Diabetes Ther 2017
20
28


Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial.
Cornelis A J van Beers, J Hans DeVries, Susanne J Kleijer, Mark M Smits, Petronella H Geelhoed-Duijvestijn, Mark H H Kramer, Michaela Diamant, Frank J Snoek, Erik H Serné. Lancet Diabetes Endocrinol 2016
171
28

Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring.
Richard M Bergenstal, Roy W Beck, Kelly L Close, George Grunberger, David B Sacks, Aaron Kowalski, Adam S Brown, Lutz Heinemann, Grazia Aleppo, Donna B Ryan,[...]. Diabetes Care 2018
169
28

Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study).
Harpreet S Bajaj, Karri Venn, Chenglin Ye, Avril Patrick, Shivani Kalra, Hasnain Khandwala, Nadeem Aslam, David Twum-Barima, Ronnie Aronson. Diabetes Care 2017
35
28

Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes.
Louis Monnier, Claude Colette, Anne Wojtusciszyn, Sylvie Dejager, Eric Renard, Nicolas Molinari, David R Owens. Diabetes Care 2017
143
28


Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial.
Roy W Beck, Tonya Riddlesworth, Katrina Ruedy, Andrew Ahmann, Richard Bergenstal, Stacie Haller, Craig Kollman, Davida Kruger, Janet B McGill, William Polonsky,[...]. JAMA 2017
451
28


Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Alan J Garber, Allen B King, Stefano Del Prato, Seamus Sreenan, Mustafa K Balci, Manuel Muñoz-Torres, Julio Rosenstock, Lars A Endahl, Ann Marie Ocampo Francisco, Priscilla Hollander. Lancet 2012
236
28

Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study.
K Khunti, S Alsifri, R Aronson, M Cigrovski Berković, C Enters-Weijnen, T Forsén, G Galstyan, P Geelhoed-Duijvestijn, M Goldfracht, H Gydesen,[...]. Diabetes Obes Metab 2016
128
28

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).
Bernard Zinman, Athena Philis-Tsimikas, Bertrand Cariou, Yehuda Handelsman, Helena W Rodbard, Thue Johansen, Lars Endahl, Chantal Mathieu. Diabetes Care 2012
225
28

Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
S Galasso, A Facchinetti, B M Bonora, V Mariano, F Boscari, E Cipponeri, A Maran, A Avogaro, G P Fadini, D Bruttomesso. Nutr Metab Cardiovasc Dis 2016
17
28

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Steven P Marso, Darren K McGuire, Bernard Zinman, Neil R Poulter, Scott S Emerson, Thomas R Pieber, Richard E Pratley, Poul-Martin Haahr, Martin Lange, Kirstine Brown-Frandsen,[...]. N Engl J Med 2017
290
28

Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial.
Yukiko Onishi, Yasuhiko Iwamoto, Soon Jib Yoo, Per Clauson, Søren C Tamer, Sungwoo Park. J Diabetes Investig 2013
75
28

Efficacy and safety of thrice-weekly insulin degludec in elderly patients with type 2 diabetes assessed by continuous glucose monitoring.
Yoshio Nagai, Mariko Murakami, Kana Igarashi, Yuta Nakamura, Hidekazu Tsukiyama, Fumiaki Matsubara, Ami Nishine, Toshihiko Ohshige, Satoshi Ishii, Hiroyuki Kato,[...]. Endocr J 2016
7
28

InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design.
Tadej Battelino, Zsolt Bosnyak, Thomas Danne, Bhaswati Mukherjee, Steve Edelman, Valerie Pilorget, Pratik Choudhary, Eric Renard, Richard Bergenstal. Diabetes Ther 2020
5
40

Basal-Bolus Insulin Therapy with Gla-300 During Hospitalization Reduces Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study.
Fumitaka Okajima, Yuko Nakamura, Yuji Yamaguchi, Yuki Shuto, Katsuhito Kato, Hitoshi Sugihara, Naoya Emoto. Diabetes Ther 2018
4
50

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml.
R H A Becker, I Nowotny, L Teichert, K Bergmann, C Kapitza. Diabetes Obes Metab 2015
77
28

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.
R E Ratner, S C L Gough, C Mathieu, S Del Prato, B Bode, H Mersebach, L Endahl, B Zinman. Diabetes Obes Metab 2013
238
28



Comparison of insulin glargine 300 U/mL and insulin degludec using flash glucose monitoring: A randomized cross-over study.
Mizuho Yamabe, Mami Kuroda, Yasuyo Hirosawa, Hiromi Kamino, Haruya Ohno, Masayasu Yoneda. J Diabetes Investig 2019
16
28

Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial.
Athena Philis-Tsimikas, David C Klonoff, Kamlesh Khunti, Harpreet S Bajaj, Lawrence A Leiter, Melissa V Hansen, Lone N Troelsen, Steen Ladelund, Simon Heller, Thomas R Pieber. Diabetologia 2020
26
28


Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3).
Timothy S Bailey, Jasmanda Wu, Fang L Zhou, Rishab A Gupta, Arjun A Menon, Paulos Berhanu, Jukka Westerbacka, John Van Vleet, Lawrence Blonde. Diabetes Obes Metab 2019
14
28


Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study.
Jeremy Pettus, Ronan Roussel, Fang Liz Zhou, Zsolt Bosnyak, Jukka Westerbacka, Rachele Berria, Javier Jimenez, Björn Eliasson, Irene Hramiak, Timothy Bailey,[...]. Diabetes Ther 2019
32
28

Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin.
Fang Liz Zhou, Fen Ye, Paulos Berhanu, Vineet E Gupta, Rishab A Gupta, Jennifer Sung, Jukka Westerbacka, Timothy S Bailey, Lawrence Blonde. Diabetes Obes Metab 2018
46
28

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
Hannele Yki-Järvinen, Richard Bergenstal, Monika Ziemen, Marek Wardecki, Isabel Muehlen-Bartmer, Emmanuelle Boelle, Matthew C Riddle. Diabetes Care 2014
181
28

[Psychometric analysis of the Spanish and Catalan versions of a questionnaire for hypoglycemia awareness].
Marga Jansa, Carmen Quirós, Marga Giménez, Merce Vidal, Mercedes Galindo, Ignacio Conget. Med Clin (Barc) 2015
27
28

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.
Tadej Battelino, Thomas Danne, Richard M Bergenstal, Stephanie A Amiel, Roy Beck, Torben Biester, Emanuele Bosi, Bruce A Buckingham, William T Cefalu, Kelly L Close,[...]. Diabetes Care 2019
734
28

Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients.
Shariq I Sherwani, Haseeb A Khan, Aishah Ekhzaimy, Afshan Masood, Meena K Sakharkar. Biomark Insights 2016
215
14


Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the Structured Testing Program study.
William H Polonsky, Lawrence Fisher, Charles H Schikman, Deborah A Hinnen, Christopher G Parkin, Zhihong Jelsovsky, Bettina Petersen, Matthias Schweitzer, Robin S Wagner. Diabetes Care 2011
256
14




Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT).
Lily Agrawal, Nasrin Azad, Gideon D Bahn, Ling Ge, Peter D Reaven, Rodney A Hayward, Domenic J Reda, Nicholas V Emanuele. Diabetologia 2018
21
14

Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial.
Feng-Fei Li, Lan-Lan Jiang, Reng-Na Yan, Hong-Hong Zhu, Pei-Hua Zhou, Dan-Feng Zhang, Xiao-Fei Su, Jin-Dan Wu, Lei Ye, Jian-Hua Ma. Medicine (Baltimore) 2016
14
14

Young onset type 2 diabetic patients might be more sensitive to metformin compared to late onset type 2 diabetic patients.
Feng-Fei Li, Bing-Li Liu, Guo-Ping Yin, Dan-Feng Zhang, Xiao-Fang Zhai, Mao-Yuan Chen, Xiao-Fei Su, Jin-Dan Wu, Lei Ye, Jian-Hua Ma. Sci Rep 2017
6
16

Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
Thomas Danne, Bertrand Cariou, John B Buse, Satish K Garg, Julio Rosenstock, Phillip Banks, Jake A Kushner, Darren K McGuire, Anne L Peters, Sangeeta Sawhney,[...]. Diabetes Care 2019
33
14

Association of 1,5-anhydroglucitol with diabetes and microvascular conditions.
Elizabeth Selvin, Andreea M Rawlings, Morgan Grams, Ronald Klein, Michael Steffes, Josef Coresh. Clin Chem 2014
41
14


High Glucose and Lipopolysaccharide Prime NLRP3 Inflammasome via ROS/TXNIP Pathway in Mesangial Cells.
Hong Feng, Junling Gu, Fang Gou, Wei Huang, Chenlin Gao, Guo Chen, Yang Long, Xueqin Zhou, Maojun Yang, Shuang Liu,[...]. J Diabetes Res 2016
73
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.